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UBE1L is a retinoid target that triggers PMLRAR
degradation and apoptosis in acute
promyelocytic leukemia
Sutisak Kitareewan*†, Ian Pitha-Rowe*, David Sekula*, Christopher H. Lowrey*‡§, Michael J. Nemeth*, Todd R. Golub¶,
Sarah J. Freemantle*, and Ethan Dmitrovsky*‡§
Departments of *Pharmacology and Toxicology and ‡Medicine, and §Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH 03755;
¶Dana Farber Cancer Institute, Boston, MA 02115; and Whitehead Institute for Biomedical Research, Cambridge, MA 02139
Communicated by William T. Wickner, Dartmouth Medical School, Hanover, NH, January 7, 2002 (received for review October 2, 2001)
All-trans-retinoic acid (RA) treatment induces remissions in acute
promyelocytic leukemia (APL) cases expressing the t(15;17) product,
promyelocytic leukemia (PML)RA receptor  (RAR). Microarray
analyses previously revealed induction of UBE1L (ubiquitin-activating
enzyme E1-like) after RA treatment of NB4 APL cells. We report here
that this occurs within 3 h in RA-sensitive but not RA-resistant APL
cells, implicating UBE1L as a direct retinoid target. A 1.3-kb fragment
of the UBE1L promoter was capable of mediating transcriptional
response to RA in a retinoid receptor-selective manner. PMLRAR, a
repressor of RA target genes, abolished this UBE1L promoter activity.
A hallmark of retinoid response in APL is the proteasome-dependent
PMLRAR degradation. UBE1L transfection triggered PMLRAR
degradation, but transfection of a truncated UBE1L or E1 did not
cause this degradation. A tight link was shown between UBE1L
induction and PMLRAR degradation. Notably, retroviral expression
of UBE1L rapidly induced apoptosis in NB4 APL cells, but not in cells
lacking PMLRAR expression. UBE1L has been implicated directly in
retinoid effects in APL and may be targeted for repression by PML
RAR. UBE1L is proposed as a direct pharmacological target that
overcomes oncogenic effects of PMLRAR by triggering its degra-
dation and signaling apoptosis in APL cells.
Acute promyelocytic leukemia (APL) (FAB M3) cases ex-press the oncogenic product of the t(15;17) rearrangement,
promyelocytic leukemia (PML)retinoic acid receptor 
(RAR), as reviewed in refs. 1 and 2. All-trans-retinoic acid
(RA) treatment causes complete remissions in these APL cases
through induction of leukemic cell differentiation (1, 2). A
hallmark of RA response in APL is PMLRAR degradation
that reverses PMLRAR oncogenic effects (3–8). Proteasomal
inhibitors prevent PMLRAR proteolysis, despite RA treat-
ment, implicating a proteasome-dependent pathway in this deg-
radation (5–8). PMLRAR expression results in dominant-
negative transcriptional repression (3, 4). This repression is
antagonized by pharmacological RA dosages that overcome
inhibitory effects on transcription of the N-CorSMRT core-
pressor complex that has histone deacetylase activity (9, 10). RA
treatment recruits a coactivator complex that stimulates tran-
scription, resulting in activation of target genes (9, 10).
Identification of RA target genes is the next step in under-
standing the molecular basis of RA response in APL. Recent
microarray analysis of RA-treated NB4 APL cells reported the
prominent induction of UBE1L (ubiquitin-activating enzyme
E1-like) (11). We examined in this study this homolog of the
ubiquitin-degradation pathway. In APL, the proteasome-
dependent degradation of PMLRAR has been proposed as a
mechanism by which RA overcomes PMLRAR oncogenic
effects. Evidence is now provided for UBE1L as a retinoid target
in APL that antagonizes PMLRAR oncogenic effects by
triggering PMLRAR degradation.
A direct relationship was found between retinoid induction of
UBE1L and degradation of PMLRAR. Examination of RA-
resistant APL cells indicated that RA induction of UBE1L did
not occur, further implicating UBE1L in retinoid response.
Expression of E1 (that has homology to UBE1L) was not
increased by RA treatment. PMLRAR cotransfected with
UBE1L (but not E1) led to PMLRAR degradation without
RA treatment. This finding indicated specificity of UBE1L for
triggering PMLRAR degradation. Results were extended by
using a UBE1L reporter assay to explore how RA regulated
UBE1L. Retroviral transduction of UBE1L caused apoptosis
only in cells that expressed PMLRAR. Findings that will be
presented here implicate UBE1L as a candidate RA target gene
responsible for a major retinoid effect in APL, degradation of
PMLRAR. Retinoid induction of UBE1L overcame PML
RAR leukemogenic actions by triggering its degradation. The
consequence of this action is the promotion of apoptosis that
further enhances the antioncogenic effects of UBE1L in APL.
Materials and Methods
Cell Culture and Induction Protocol. RA and DMSO were purchased
from Sigma. Stock RA (10 mM) solutions were dissolved in DMSO,
stored in liquid nitrogen, and used in the dark during experiments.
RPMI 1640 and -MEM were purchased from CellgroMediatech,
Herndon, VA. The NB4 APL cell line expresses PMLRAR (12).
NB4-S1 and NB4-R1 are RA-sensitive and RA-resistant clones of
NB4 cells, respectively (13). These cells were cultured in RPMI 1640
media supplemented with 10% FBS as described (13). Chinese
hamster ovary (CHO) cells were cultured in -MEM supplemented
with 5% FBS, 100 unitsml penicillin, 100 unitsml streptomycin,
and 2 mM L-glutamine in a 5% CO2 humidified incubator at 37°C.
Human bronchial epithelial cells (BEAS-2B) were cultured in
serum-free LHC-9 medium (Biofluids, Rockville, MD) by using
established techniques (14, 15). HeLa cells were cultured in
DMEM supplemented with 10% FBS, 100 unitsml penicillin, 100
unitsml streptomycin, and 2 mM L-glutamine in a 5% CO2
humidified incubator at 37°C.
Differentiation and Apoptosis Markers. NB4 cell differentiation was
scored by using the nitroblue tetrazolium (NBT) reduction assay
(13, 16, 17). Transductants were identified by green fluorescent
protein (GFP) coexpression. Apoptosis was scored by using estab-
lished techniques and Hoechst staining of transductants that co-
expressed GFP (16–18). Digital images were collected by using an
Olympus 170 inverted microscope, a cooled charge-coupled
Abbreviations: APL, acute promyelocytic leukemia; PML, promyelocytic leukemia; RAR,
retinoic acid receptor ; RA, all-trans retinoic acid; UBE1L, ubiquitin-activating enzyme
E1-like; GFP, green fluorescent protein; NBT, nitroblue tetrazolium; CHO, Chinese hamster
ovary; HA, hemagglutinin; MSCV, murine stem cell virus.
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device camera, and a MiraCal Pro Single Cell Imaging System
(Olympus LSR Research, Melville, NY).
Plasmid Constructs. A full-length UBE1L cDNA containing plasmid
was obtained from C. H. C. M. Buys (University of Groningen,
Groningen, the Netherlands). A. Schwartz (Washington University
School of Medicine, St. Louis) provided the pGEM-HA-1E1
plasmid, and pSG5-HA-1E1 was constructed by cloning the HA-
1E1 fragment into the pSG5 expression vector. An EcoR1 fragment
containing the UBE1L cDNA was cloned into EcoRI-retricted
pSG5 to yield the pSG5-UBE1L plasmid. A truncated UBE1L
plasmid (UBE1L-T) removed an EclXISnaBI fragment from
pSG5-UBE1L that deleted a large portion of the carboxyl terminus
of UBE1L. The hemagglutinin (HA)-tagged PMLRAR expres-
sion vector was constructed from pCMX-PMLRAR and
pCMV-HA (CLONTECH) plasmids. The pGL3-UBE1L-Luc re-
porter plasmid contained the luciferase gene and 5 promoter
elements of UBE1L. It was constructed by using an amplified
fragment of the UBE1L promoter derived from NB4-S1 genomic
DNA (forward primer: 5-GCAACCGAGTGAGACTGTCT-3;
reverse primer: 5-GCGCTCAGAGATAGGGTCTTT-3). DNA
sequence analysis confirmed this cloning.
UBE1L mRNA Expression Assays. UBE1L mRNA expression was
assessed by a reverse transcription–PCR assay and established
methods (3). The forward primer was 5-AGGTGGCCAA-
GAACTTGGTT-3, and reverse primer was 5CACCACCTG-
GAAGTCCAACA-3. The PCR product was visualized by
probing with a 32P-labeled primer. Results were confirmed
independently by Northern analysis using a 1.0-kb EcoRINcoI-
radiolabeled UBE1L probe and standard techniques (14). This
probe had limited homology to E1.
Generation of Anti-UBE1L Antisera. Rabbit polyclonal antibodies
were independently derived (Covance Research Products, Den-
ver, PA) against UBE1L by using one peptide within the amino
terminus (DCDPRSIHVREDGSLEIGD) and a second peptide
within the carboxyl terminus (PGSQDWTALRELLKLL).
Specificities of these antisera were confirmed by immunoblot
analyses of UBE1L-transfected CHO cells.
Immunoblot Analysis. Immunoblot analyses were performed by
using established techniques (14, 19). Anti-RAR antibody was
provided by P. Chambon (Institut National de la Santé et de la
Recherche Médicale, Strasbourg, France) to detect PML
RAR (16, 17). An anti-HA mAb was purchased (Babco,
Richmond, CA) as was an anti-actin polyclonal antibody, C-11
(Santa Cruz Biotechnology).
Transfection Procedure. Transient transfection of BEAS-2B or
CHO cells was accomplished by using Effectene and transfection
methods as per the manufacturer (Qiagen, Valencia, CA). A
-galactosidase reporter plasmid (pCH111) was cotransfected to
control for transfection efficiencies.
Retroviral Constructs and Transduction Procedures. Murine stem cell
virus (MSCV)-IRES (internal ribosome entry sequence)-GFP was
constructed to express UBE1L cDNA by cloning an EcoRI frag-
ment from pSG5-UBE1L into an EcoRI site of this retroviral
vector. Restriction endonuclease and partial DNA sequence anal-
yses confirmed cloning was in the desired orientation. A vector
without an insert served as a control. For each vector, 10 g was
transiently transfected by using calcium phosphate precipitation
along with the CellPhect Transfection kit (Amersham Pharmacia).
The 293GPG packaging cell line was provided by R. Mulligan
(Harvard University, Cambridge). Forty-eight hours later, viral
supernatant from 293GPG transfectants (20) was used to transduce
NB4-S1 or HeLa cells in the presence of 6 gml polybrene
(Sigma). Twenty-four hours later, FACS analysis was performed,
and cells positive for GFP expression were harvested by sorting and
used for these experiments.
Results
RA Induction of UBE1L mRNA. UBE1L mRNA was reported as
induced after RA treatment of APL cells (11). The kinetics of
this induction was studied in RA-sensitive NB4-S1 APL cells by
using a reverse transcription–PCR assay (Fig. 1). UBE1L mRNA
expression increased rapidly after RA treatment. UBE1L in-
duction occurred by 3 h after 10 M RA treatment (Fig. 1). This
was independently confirmed by Northern analysis (data not
shown) and after 1 M RA treatment by reverse transcription–
PCR assay (data not shown). In contrast, UBE1L expression was
not induced during the same time period, despite 10 M RA
treatment of the RA-resistant NB4-R1 cell line (data not
shown). Differential UBE1L expression implicated a role for
UBE1L in regulating growth or differentiation of APL cells.
RA Induction of UBE1L Protein. UBE1L immunoblot expression was
examined. As discussed in Materials and Methods, immunogenic
peptides generated independent polyclonal antisera recognizing
the amino or carboxyl termini of UBE1L protein. CHO cells that
did not basally express UBE1L mRNA (data not shown) were
transfected with a full-length UBE1L cDNA or an insertless
vector. CHO cells transfected with UBE1L expressed UBE1L
protein whereas cells transfected with an insertless vector did not
express this 112-kDa species (Fig. 2A). UBE1L immunoblot
expression profiles were compared in RA-sensitive versus RA-
resistant NB4 cells. UBE1L protein was basally expressed at low
levels in both cell lines. It was induced only after RA (1 M)
treatment of NB4-S1 APL cells (Fig. 2B). These findings impli-
cated a direct relationship between UBE1L induction and
effective retinoid treatment of APL cells.
A hallmark of RA response in APL is PMLRAR degra-
dation (5–8). RA treatment repressed PMLRAR expression
in NB4-S1, but not in NB4-R1 cells (13). To examine the
relationship in APL cells between UBE1L and PMLRAR
expression, immunoblot expression profiles for these species
were examined before and after RA (1 M) treatment of
NB4-S1 cells. An inverse relationship was evident between
UBE1L and PMLRAR expression both before and after RA
treatment (Fig. 2C). This finding suggested a direct role for
PMLRAR in regulating UBE1L expression.
Induction of UBE1L Reporter Activity. To examine further the po-
tential for PMLRAR to affect UBE1L, 1.3 kb of the UBE1L
promoter upstream of the ATG translation start site was cloned into
a luciferase-containing reporter plasmid. This reporter plasmid was
Fig. 1. UBE1L mRNA induction in RA-treated NB4-S1 APL cells. UBE1L
expression was induced within 3 h of RA treatment in this reverse transcrip-
tion–PCR assay, implicating a role for UBE1L in RA response of APL cells. No
appreciable change in UBE1L expression occurred in RA-untreated controls.
-actin expression confirmed similar loading in each lane.











transfected into CHO cells in the presence and absence of RA
treatment (Fig. 3A). This fragment of the UBE1L promoter was
capable of mediating transcriptional response to RA in a retinoid
receptor-selective manner.
The relationship between PMLRAR and activity of this
UBE1L reporter plasmid was examined when PMLRAR was
cotransfected with this reporter plasmid. Cotransfection of PML
RAR with RAR led to a marked repression of UBE1L reporter
activity before and after RA (1 M) treatment. This inhibition
depended on the dosage of transfected PMLRAR (Fig. 3B). In
each experiment, a cotransfected -galactosidase reporter plasmid
was used to control for tranfection efficiencies. No appreciable
effect of PMLRAR on the transcriptional activity of the -ga-
lactosidase reporter plasmid was observed (data not shown). Thus,
PMLRAR repressed activity of this UBE1L reporter plasmid.
Lack of E1 Induction by RA. UBE1L has homology to E1. Whether
RA treatment induced E1 expression in APL cells was examined.
E1 mRNA was not induced after RA (1 M) treatment of
NB4-S1 cells (data not shown), indicating different effects of RA
on expression of UBE1L and E1. The ability of UBE1L or E1 to
trigger PMLRAR degradation was next examined.
UBE1L Triggers PMLRAR Degradation. Cotransfection assays used
cells that did not express PMLRAR. Experiments used CHO
cells that did not express UBE1L and BEAS-2B cells that expressed
low levels of UBE1L, but could be readily transfected with RARs
or PMLRAR. Degradation of transfected PMLRAR was
triggered by UBE1L in a dose-dependent manner after transfection
of CHO cells (data not shown) or BEAS-2B cells (Fig. 4A). This
degradation of PMLRAR occurred in the absence of RA
treatment. Transfection of a truncated UBE1L (pSG5-UBE1L-T)
did not cause PMLRAR degradation (Fig. 4B). To establish that
PMLRAR degradation was a distinct UBE1L function, E1 was
transfected into BEAS-2B cells with PMLRAR. E1 did not cause
PMLRAR degradation (Fig. 4B).
UBE1L Expression Triggers Apoptosis in APL Cells. Transfection of
UBE1L, but not E1, led to PMLRAR degradation even without
RA treatment. It was next examined whether engineered overex-
pression of UBE1L in APL cells would alter the growth or
differentiation state of these cells. To accomplish this, retroviral
vectors (20) were constructed to express UBE1L or no insert.
Coexpressed GFP was used to enrich for retroviral-expressing cells
after FACS sorting. HeLa cells, which do not express PMLRAR
and basally express UBE1L at low levels (Fig. 5A and data not
shown), were used as a control for these experiments because
retroviral transduction conditions were previously optimized in
these cells. UBE1L overexpression was engineered independently
in NB4-S1 and HeLa cells (Fig. 5A) using the described retroviral
transduction method. As a control, an insertless control vector was
independently introduced into these cell lines, as confirmed by
immunoblot analysis (Fig. 5A). A striking difference in biological
effects was observed after transduction of UBE1L into NB4-S1
versus HeLa cells. UBE1L overexpression in NB4-S1 cells resulted
in the rapid induction of apoptosis as shown by the Hoechst staining
of transduced cells (Fig. 5B). Three independent fields were exam-
ined for the insertless control NB4-S1 transfectants and 5.1% of
these cells were apoptotic. Analysis of UBE1L-transduced NB4-S1
cells revealed a high proportion (39.7%) of apoptotic cells. These
Fig. 2. Immunoblot assays for UBE1L expression. (A) Immunogenic peptides generated anti-UBE1L polyclonal antisera recognizing, respectively, the carboxyl
or amino termini of human UBE1L. UBE1L immunoblot assays were performed in transfected CHO cells. The 112-kDa UBE1L species was detected by using either
antisera.  and  refer to transfection () of pSG5-UBE1L or an insertless control pSG5 vector (). Molecular mass size markers are depicted. (B) UBE1L protein
was induced by 24 h of RA (1 M) treatment of NB4-S1 but not NB4-R1 cells, as assayed by using the anti-UBE1L amino terminus antibody. (C) An inverse
relationship existed between UBE1L and PMLRAR protein expression before and after RA treatment of NB4-S1 cells. UBE1L expression was induced and
PMLRAR expression was repressed after 24 h of RA treatment of these cells. In B and C, actin expression confirmed similar protein loading in each lane.
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transductants did not exhibit morphological evidence of leukemic
cell maturation. This lack of induced differentiation was confirmed
by the absence of NBT-positive cells (Table 1). Notably, promotion
of apoptosis was not observed in HeLa cells transduced with either
the UBE1L or insertless retroviral vector (data not shown). Thus,
UBE1L transduction preferentially triggered apoptosis in PML
RAR-expressing cells.
Discussion
This study demonstrates that UBE1L is a candidate RA target gene
in APL. Several lines of evidence supported this view. UBE1L
expression was induced by RA treatment of differentiation sensi-
tive, but not resistant APL cells (Figs. 1 and 2). The UBE1L
promoter was capable of mediating transcriptional response to RA
in a retinoid receptor-selective manner. It is not known whether
these transcriptional effects are direct, but it is notable that the
UBE1L promoter contained several putative RA response element
half-sites. PMLRAR inhibited UBE1L reporter activity (Fig. 3).
A hallmark of RA response in APL is PMLRAR degradation.
Direct evidence for UBE1L involvement in this degradation came
from experiments where UBE1L and PMLRAR cotransfection
led to PMLRAR degradation (Fig. 4). Preliminary findings
indicated that the PML domain of PMLRAR was more sensitive
to degradation by UBE1L than the RAR domain (I.P.-R., un-
published work). These UBE1L effects were specific because RA
treatment failed to induce E1 expression and cotransfection of E1
with PMLRAR did not cause PMLRAR degradation. Thus,
UBE1L and E1 functions are distinct. These results were consistent
with a report that demonstrated different biochemical properties of
UBE1L and E1 regarding complex formation (21).
Findings reported here are consistent with an antagonistic
relationship between UBE1L and PMLRAR in APL. To
determine UBE1L biological effects in APL cells, UBE1L was
overexpressed in these cells by using a retroviral approach (Fig.
5). Whereas an insertless control retroviral vector could be
readily expressed in NB4-S1 cells, the UBE1L retroviral vector
could not because apoptosis was rapidly triggered. This occurred
without evidence for induced maturation (Fig. 5 and Table 1).
Induction of apoptosis was so rapid that examination of the
mechanisms signaling apoptosis was precluded. These effects
were specific to APL cells because transduction of the UBE1L
or control retroviral vector did not trigger apoptosis in HeLa
cells that lacked PMLRAR expression.
These findings were not unexpected. Previous work with
hammerhead ribozymes that target PMLRAR indicated how
PMLRAR degradation signaled apoptosis but not differen-
tiation in transfected APL cells that were either RA-sensitive or
RA-resistant (16, 17). Catalytic ribozymes must be introduced
into APL cells for their overexpression to trigger apoptosis. This
requirement could limit therapeutic activity of these ribozymes
even though they might exert limited biological effects beyond
PMLRAR catalysis. In contrast, UBE1L induction by RA
should be clinically achievable. Whether RA is the optimal agent
to induce UBE1L expression in APL cells is not yet known. A
pharmacological agent that preferentially induced UBE1L ex-
pression might exhibit therapeutic activity in APL.
RA treatment signaled myeloid differentiation and degradation
of PMLRAR without triggering appreciable apoptosis (5–8, 16,
17). Transcriptional activation by RA treatment likely exerts diverse
effects in APL cells in addition to PMLRAR degradation and
Fig. 3. UBE1L reporter assays in CHO cells cotransfected with RARs or
PMLRAR. (A) Cotransfection of RARs activated this UBE1L reporter plasmid,
but to differing degrees after RA (10 M) treatment. (B) PMLRAR cotrans-
fection with the UBE1L reporter plasmid inhibited transcriptional activation in
a dose-dependent manner. PMLRAR inhibition was antagonized by RA (1
M) treatment. In this experiment, pSG5-RAR was cotransfected (0.125 g)
because this retinoid receptor most efficiently induced UBE1L transcriptional
activity, as shown in A. SD bars are depicted.
Fig. 4. UBE1L transfection triggered PMLRAR degradation. (A) Cotrans-
fection of PML-RAR (HA-tagged) with UBE1L led to PMLRAR degradation.
This depended on the transfected UBE1L dosage (closed triangle). Molecular
mass size markers are depicted. The symbols  and  refer to transfection of
PMLRAR or UBE1L, respectively. (B) Cotransfection of E1 (pSG5-E1) or a
truncated UBE1L (pSG5-UBE1L-T) did not cause PMLRAR degradation. Both
PMLRAR and E1 were HA-tagged and an anti-HA antibody was used,
accounting for dual detection in the fourth lane. Intact UBE1L was required for
this PMLRAR degradation.  and  refer to transfection of pCMV-PML
RAR, pSG5-UBE1L, pSG5-UBE1L-T, or pSG5-E1, respectively. Molecular mass
size markers are displayed.











myeloid differentiation. Regarding PMLRAR degradation after
RA treatment, previous work indicated how this could occur
through proteasomal as well as caspase-dependent pathways (7, 8).
These pathways are reported as linked in some cell contexts,
including thymocytes and sympathetic neurons (22, 23). Perhaps
RA treatment links these pathways in APL cells.
Future work will determine the biochemical relationship
between UBE1L and PMLRAR degradation. Findings re-
ported here are consistent with previous work indicating that RA
promoted ubiquitination and cyclin degradation during retinoid-
induced differentiation or growth suppression (14, 15, 19).
Recent evidence highlighted the tumor-selective death ligand,
TRAIL, in induction of apoptosis in APL cells (24). It would be
interesting to determine whether UBE1L plays a role in TRAIL-
mediated death signaling by retinoids.
Arsenic trioxide treatment also caused apoptosis and PML
RAR degradation without prominent induction of differenti-
ation in APL (8, 25, 26). It was reported to trigger PMLRAR
proteolysis through covalent modification with PIC-1SUMO
(26). Arsenic trioxide proteolytic effects could differ from those
of RA treatment. Consistent with this view, preliminary findings
indicated that UBE1L induction did not occur after arsenic
trioxide treatment of NB4 cells (S.K., unpublished work).
UBE1L retroviral expression in APL cells might confer more
limited biological effects than treatments with either arsenic
trioxide or RA. UBE1L biochemical targets in APL should be
determined. Agents that selectively induce UBE1L expression in
APL could cause antileukemic effects by triggering PMLRAR
Fig. 5. (A) UBE1L immunoblot expression in HeLa and NB4-S1 cells independently transduced with retroviral vectors that expressed UBE1L or no insert. Lanes
represent HeLa cells 7 days after transduction with an insertless retroviral vector (first lane) or UBE1L retroviral vector (second lane); NB4-S1 cells 5 days after
transduction with an insertless retroviral vector (third lane) or the UBE1L retroviral vector (fourth lane). UBE1L expression in MSCV-UBE1L transductants was
increased over that in HeLa or NB4-S1 cells after introduction of the MSCV vector. Actin expression confirmed similar protein loading. Molecular mass size markers
are depicted. (B) UBE1L retroviral expression triggered apoptosis in NB4-S1 but not HeLa cells. The control vector (MSCV-Vector) was expressed in NB4-S1 cells
without observed growth or differentiation effects (Left and Table 1). In marked contrast, when UBE1L (MSCV-UBE1L) was introduced, rapid induction of NB4-S1
cell death occurred through triggering of apoptosis as shown by appearance of fragmented nuclei in Hoechst-stained cells (Right and text). Representative fields
are depicted. This was not observed after introduction of the control (MSCV-Vector) or UBE1L retroviral vector (MSCV-UBE1L) into HeLa cells that do not express
PMLRAR (data not shown).
Table 1. NBT maturation assays performed on NB4-S1 APL cells
after 5 days of treatment with RA (1 M) [designated RA] or
vehicle (DMSO) [designated RA] or transduction of the UBE1L
retrovirus, [designated UBE1L] as compared to transduction of
the same retrovirus without an insert [designated UBE1L]





NBT-positive NB4-S1 cells appeared after RA treatment, but transduction of
UBE1L or a control vector did not induce morphological maturation (data not
shown) or a positive NBT assay. For each assay, 200 cells were scored and
percentages of NBT-positive cells are shown.
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degradation and apoptosis, perhaps without undesirable clinical
toxicities that complicate RA or arsenic trioxide treatments.
Few candidate RA target genes have been reported in APL.
GOS2 is a putative RA target gene identified by microarray
analysis of APL cells (11). The precise function of G0S2 is not
yet known, but it was first identified as regulated during the cell
cycle (27), suggesting a role in cell cycle control. Another
candidate retinoid target gene is the CCAATenhancer binding
protein  (CEBP) that contributes to retinoid transcriptional
effects in APL (28). In contrast to these species, UBE1L could
account for an important posttranscriptional retinoid effect in
APL, PMLRAR degradation. An in-depth examination of
retinoid-regulated species identified by microarray analyses (11)
would provide a fuller understanding of the acute promyelocytic
differentiation program.
E1 and UBE1L exhibited distinct functions. Based on findings
presented here and previous work (21), UBE1L may have an
important biological role beyond APL. UBE1L maps to chro-
mosome 3p, a region frequently deleted in lung cancers; UBE1L
repression is frequent in lung cancers (29, 30) where it may exert
a tumor suppressive effect. This possibility, when coupled with
the expression pattern of UBE1L in human tissues or tumor cells
(ref. 31 and I.P.-R., unpublished work) and results of UBE1L
retroviral transduction reported here, indicates that UBE1L
might regulate growth of normal or neoplastic cells.
How UBE1L triggers PMLRAR degradation should be
determined. It has not been excluded that UBE1L affects
transcription, translation, or PMLRAR stability, independent
of ubiquitin-dependent proteolysis. Perhaps UBE1L complexes
with another protein that would cause PMLRAR degrada-
tion. In this regard, complex of UBE1L to the ubiquitin-like
protein ISG15 has been reported (21). Perhaps RA promotes
ISG15-dependent modification of PMLRAR and thereby
targets PMLRAR for degradation.
In summary, this study identified UBE1L as a candidate retinoid
target gene in APL. This view was based on the rapid induction of
UBE1L after RA treatment of differentiation sensitive but not
resistant NB4 APL cells. An antagonistic relationship between
UBE1L and PMLRAR was uncovered. PMLRAR oncogenic
effects were overcome by RA induction of UBE1L that triggers
PMLRAR degradation. Apoptosis was signaled when UBE1L
was introduced into APL but not control cells that lacked PML
RAR expression. UBE1L triggered PMLRAR degradation
and antioncogenic effects, but did not signal a maturation response.
Differentiation may depend on other target genes. Future work will
determine which agents optimally augment UBE1L expression and
how UBE1L causes PMLRAR degradation. UBE1L could play
an important biological role beyond APL. In APL, retinoid induc-
tion of UBE1L abolished PMLRAR leukemogenic effects by
targeting it for degradation. This triggered apoptosis, further en-
hancing antioncogenic actions of UBE1L in APL. Taken together,
these findings indicate how UBE1L induction accounted for a
major retinoid therapeutic effect in APL, the degradation of
PMLRAR.
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Quignon, F., Rochette-Egly, C. & de Thé, H. (1999) Proc. Natl. Acad. Sci. USA
96, 14807–14812.
9. Lin, R. J., Nagy, L., Inoue, S., Shao, W., Miller, W. H., Jr. & Evans, R. M. (1998)
Nature (London) 391, 811–814.
10. Grignani, F., de Matteis, S., Nervi, C., Tomassoni, L., Gelmetti, V., Cioce, M.,
Fanelli, M., Ruthardt, M., Ferrara, F. F., Zamir, I., et al. (1998) Nature
(London) 391, 815–818.
11. Tamayo, P., Slonim, D., Mesirov, J., Zhu, Q., Kitareewan, S., Dmitrovsky, E.,
Lander, E. S. & Golub, T. R. (1999) Proc. Natl. Acad. Sci. USA 96, 2907–2912.
12. Lanotte, M., Martin-Thouvenin, V., Najman, S., Balerini, P., Valensi, F. &
Berger, R. (1991) Blood 77, 1080–1086.
13. Nason-Burchenal, K., Maerz, W., Albanell, J., Allopenna, J., Martin, P.,
Moore, M. A. S. & Dmitrovsky, E. (1997) Differentiation 61, 321–331.
14. Langenfeld, J., Kiyokawa, H., Sekula, D., Boyle, J. & Dmitrovsky, E. (1997)
Proc. Natl. Acad. Sci. USA 94, 12070–12074.
15. Boyle, J. O., Langenfeld, J., Lonardo, F., Sekula, D., Reczek, P., Rusch, V.,
Dawson, M. I. & Dmitrovsky, E. (1999) J. Natl. Cancer Inst. 91, 373–379.
16. Nason-Burchenal, K., Allopenna, J., Bègue, A., Stéhelin, D., Dmitrovsky, E. &
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